Oryzon Genomics S.A.
Symbol: 0RDB.L
LSE
1.97
EURTržní cena dnes
-34.0078
Poměr P/E
-1.5775
Poměr PEG
123.58M
MRK Cap
- 0.00%
Výnos DIV
Oryzon Genomics S.A. (0RDB-L) finanční výkazy
Rozvaha
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 22.8 | 32.7 | 48.4 | |||||||||||
balance-sheet.row.short-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0.1 | 0.4 | |||||||||||
balance-sheet.row.other-current-assets | 0 | 4.1 | 4.3 | 3 | |||||||||||
balance-sheet.row.total-current-assets | 0 | 26.9 | 37.1 | 51.8 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 0.7 | 0.8 | 0.8 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0.6 | 0.7 | 0.3 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0.6 | 0.7 | 0.3 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 82.9 | 70 | 62.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 0 | 84.1 | 71.5 | 63.2 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 0 | 111 | 108.6 | 115 | |||||||||||
balance-sheet.row.account-payables | 0 | 5.4 | 3.3 | 2.4 | |||||||||||
balance-sheet.row.short-term-debt | 0 | 13 | 4.7 | 5.9 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0 | 11.1 | 15.2 | 10.6 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 0 | 1.6 | 1.8 | 1 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 13.3 | 17.6 | 12.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0.1 | 0 | 0 | |||||||||||
balance-sheet.row.total-liab | 0 | 33.3 | 27.5 | 22.2 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 3 | 3 | 3.2 | |||||||||||
balance-sheet.row.retained-earnings | 0 | -13.1 | -9.2 | -4.1 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 3.2 | 3.8 | 4.1 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 84.7 | 83.4 | 89.5 | |||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 77.7 | 81.1 | 92.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 111 | 108.6 | 115 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 0 | 77.7 | 81.1 | 92.8 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||
Total Investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-debt | 0 | 24.1 | 19.9 | 16.5 | |||||||||||
balance-sheet.row.net-debt | 0 | 1.3 | -12.8 | -31.8 |
Výkaz peněžních toků
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | -3.7 | -4.5 | -5.3 | ||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 0.2 | 0.2 | ||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | 0.4 | 1.1 | ||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0.3 | -0.1 | ||||||||||||
cash-flows.row.inventory | 0 | 0 | 0.1 | 0.2 | ||||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | 0 | 0.9 | ||||||||||||
cash-flows.row.other-non-cash-items | 0 | 3.7 | 2 | 0 | ||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.1 | -0.2 | ||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -15.2 | -13.1 | ||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -15.3 | -13.3 | ||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -0.7 | -4.7 | ||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -1.1 | 0 | ||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | ||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | 9.7 | 4.1 | ||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | 9.3 | 4.7 | ||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0.4 | ||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | -9.9 | -15.7 | ||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 22.8 | 22.8 | 32.7 | ||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 22.8 | 32.7 | 48.4 | ||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | -2 | -4.1 | ||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.1 | -0.2 | ||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | -2.1 | -4.3 |
Řádek výkazu zisku a ztráty
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | 16.8 | 12.1 | ||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 0 | 0.5 | 0.8 | ||||||||||||
income-statement-row.row.gross-profit | 0 | 0 | 16.3 | 11.2 | ||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.operating-expenses | 0 | 5 | 22.1 | 18.9 | ||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 5 | 22.6 | 19.7 | ||||||||||||
income-statement-row.row.interest-income | 0 | 1.3 | 0 | 0 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -1.1 | -0.4 | ||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | ||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | 17.2 | -1.1 | -0.2 | ||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | ||||||||||||
income-statement-row.row.total-operating-expenses | 0 | 17.2 | -1.1 | -0.2 | ||||||||||||
income-statement-row.row.interest-expense | 0 | 0 | -1.1 | -0.4 | ||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 0.2 | 0.2 | 0.2 | ||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | ||||||||||||
income-statement-row.row.operating-income | 0 | -20.9 | -5.9 | -8 | ||||||||||||
income-statement-row.row.income-before-tax | 0 | -3.7 | -7 | -8.2 | ||||||||||||
income-statement-row.row.income-tax-expense | 0 | 0 | 2.5 | 2.8 | ||||||||||||
income-statement-row.row.net-income | 0 | -3.7 | -4.5 | -5.3 |
Často kladené otázky
Co je Oryzon Genomics S.A. (0RDB.L) celková aktiva?
Oryzon Genomics S.A. (0RDB.L) celková aktiva jsou 111039575.000.
Jaký je roční obrat podniku?
Roční příjmy jsou N/A.
Jaké je ziskové rozpětí podniku?
Zisková marže firmy je 0.983.
Jaký je volný peněžní tok podniku?
Volný peněžní tok je 0.000.
Jaká je čistá zisková marže podniku?
Čistá zisková marže je -0.447.
Jaké jsou celkové tržby podniku?
Celkové příjmy jsou -1.500.
Co je Oryzon Genomics S.A. (0RDB.L) čistý zisk (čistý příjem)?
Čistý zisk (čistý příjem) je -3705000.000.
Jaký je celkový dluh podniku?
Celkový dluh je 24113573.000.
Jaké je číslo provozních nákladů?
Provozní výdaje jsou 5027000.000.
Jaké je číslo peněžních prostředků firmy?
Peněžní prostředky podniku jsou 0.000.